Vyome Holdings, Inc. (NASDAQ:HIND) Given Consensus Rating of “Hold” by Analysts

Vyome Holdings, Inc. (NASDAQ:HIND) has earned an average recommendation of “Hold” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $15.00.

Several brokerages recently issued reports on HIND. Zacks Research raised Vyome to a “hold” rating in a report on Wednesday, May 6th. Litchfield Hills Research began coverage on Vyome in a report on Monday, May 4th. They issued a “buy” rating on the stock. Finally, Weiss Ratings raised Vyome from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st.

Vyome Trading Up 2.4%

Shares of HIND opened at $2.16 on Friday. The firm has a market cap of $15.16 million, a price-to-earnings ratio of -0.18 and a beta of 1.48. Vyome has a 52 week low of $1.75 and a 52 week high of $18.60. The stock has a 50 day moving average of $2.16 and a 200-day moving average of $2.66.

Vyome (NASDAQ:HIND) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million during the quarter. Vyome had a negative return on equity of 203.92% and a negative net margin of 270.58%. On average, sell-side analysts predict that Vyome will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of Vyome

An institutional investor recently bought a new position in Vyome stock. Geode Capital Management LLC bought a new stake in shares of Vyome Holdings, Inc. (NASDAQ:HIND) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned approximately 0.21% of Vyome at the end of the most recent reporting period. Institutional investors and hedge funds own 22.06% of the company’s stock.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.